ratings

5 Biotechs Leerink Analysts Are Watching – Benzinga

Related FOLDMid-Morning Market Update: Markets Gain; Finish Line Beats Q1 ViewsMorning Market GainersRelated IPXLUS Stock Futures Signal Higher Start On Wall StreetImpax Announces Sale of Daraprim to Turing Pharmaceuticals AG , ~$55MAquinox’s Shares Shoot Up, Bladder Pain Drug in Focus(Zacks)In a recent report, analysts at Leerink shared their views on a ton of biotech stocks. Here is a look at […]

The Historical Correlation Between Biotech Stocks And … – Benzinga

Related AMGNSocial Media Beat: What The Crowd & Experts Think Of Oil, Biotech & LinkedInStocks Hitting 52-Week HighsAre You Ready For A Pullback BIIB AMGN GILD CELG UTHR JAZZ GOOG FB NFLX APA APC EOG PANW DO RIG(Marketfy Insights)Related CELG5 Biotechs With Catalysts Coming This WeekIs More M&A On The Way For Large-Cap Biotechs?Are You Ready For A Pullback BIIB […]

Two Stocks in My Favorite Industry Sector

The Dow Jones has been zigzagging nearly all year long. Everyone knows that.Transportation stocks, basic materials and commodities have been sagging, even plunging. Most people know that, too.What many people may not be aware of — or may be underestimating — is the strength and sustainability of one key sector that’s been making investors money through thick and thin: health […]

Stifel Talks 5 Biotech Stocks – ARIAD Pharmaceuticals, Inc …

Related ARIAMorning Market GainersBenzinga’s Top #PreMarket GainersThe Vetr community has downgraded $ARIA to 3-Stars(Vetr)Related CLVSGoldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis OncologyBenzinga’s Volume MoversStifel analyst Brian Klein published abstracts Thursday from the 2015 ASCO annual meeting.Klein’s following comments along with current ratings were intended to provide investors with “meaningful insight into ongoing clinical activities for various […]

Oppenheimer Comments On 2 Biotech Stocks – Benzinga

Related CNCOppenheimer Boosting Targets In Healthcare On ‘Exposure To Interest Rate Changes’8 Managed Care Stocks To Watch In Earnings Season’Non-Cyclical Consumer Healthcare’: How This Sector Will Create Long-Term Wealth(Seeking Alpha)Related Biotech: Anatomy Of An Investing Mania?Bind Therapeutics Rallies Off Oppenheimer RatingIn separate reports, Oppenheimer analysts commented on the pipelines of two Biotech majors – Centene Corp (NYSE: CNC) and BIND […]

2 Biotech Stocks Deutsche Bank Just Initiated – Sagent … – Benzinga

Related SGNT5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 YearsPorat To Google Just One Of The Week’s Top Management Changes; Here Are 7 MoreRelated IPXLFTC Requires Divestitures in Connection With Impax Laboratories Inc.’s Proposed Acquisition of CorePharma, LLCJPM Securities Picks Through Biotech News For WinnersMylan makes $205/share bid for Perrigo; Generic firms rally(Seeking Alpha)Shares of […]

5 Biotech Stocks On JMP's Radar – (BIND), (CERU) | Benzinga

Related 13 Management Changes That Happened This Week8-K Filing Shows Bind Therapeutics Closes Offering Of StockRelated Morning Market LosersCerulean Announces Completion of Enrollment of a Phase 1b/2 Study of CRLX101 in Combination with Avastin® in Relapsed Renal Cell CarcinomaCerulean Pharma (CERU) Shares March Higher, Can It Continue? – Tale of the Tape(Zacks)In a recent report, analysts at JMP Securities discussed […]

Maxim Sees Major Upside In These Biotech Stocks – Athersys, Inc …

Related ATHXMorning Market GainersWhy Investors Are Watching Athersys Ahead Of Stem Cell DataIn a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here’s a rundown of what they had to say.Athersys, Inc. (NASDAQ: ATHX)Analysts believe that Athersys may have found a “sweet spot” for stroke treatment timing, as […]

Maxim Sees Major Upside In These Biotech Stocks

In a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here’s a rundown of what they had to say.Athersys, Inc. (NASDAQ: ATHX)Analysts believe that Athersys may have found a “sweet spot” for stroke treatment timing, as data from a phase II trial of MultiStem treatment one to two […]

Barclays Expands Coverge To 7 New Biotech Stocks

Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]